Proteomic mass spectrometry can identify key biomarkers in IPF, aiding in diagnosis and prognosis despite the disease's ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...

A hybrid model combining LM, GA, and BP neural networks improves TCM's diagnostic accuracy for IPF, achieving 81.22% ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...

Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of "a partially-blinded ...

BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of ...

Please provide your email address to receive an email when new articles are posted on . Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved ...

INGELHEIM, Germany--(BUSINESS WIRE)--New results from a global survey supported by Boehringer Ingelheim 1 reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis ...

Please provide your email address to receive an email when new articles are posted on . Researchers found differences between the two settings when evaluating the number of patients who agreed with ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...